Fig. 6

Patients who were insensitive to both Herceptin and TKI but sensitive to immunotherapy were analyzed separately. A The gene mutation landscape of APOB, TBC1D32, and XAB2; B Kaplan-Meier survival analysis of APOB; C-F Immune infiltration level of CD8+ T cell, Macrophage, NK cell activated, and T cell follicular helper cell between WT APOB and Mutated APOB in patients with breast cancer. G Drug-gene interactions. 18 drugs were obtained that had potential therapeutic effects for targeting APOB